Icon (NASDAQ:ICLR) Given New $150.00 Price Target at Barclays

Icon (NASDAQ:ICLR) had its price target lifted by Barclays from $120.00 to $150.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the medical research company’s stock.

ICLR has been the topic of several other research reports. Royal Bank Of Canada boosted their price target on Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research note on Friday. Leerink Partners set a $145.00 price target on Icon in a research note on Thursday. Jefferies Financial Group set a $135.00 price target on Icon and gave the stock a “buy” rating in a research note on Monday, February 23rd. TD Cowen upgraded Icon from a “hold” rating to a “buy” rating and cut their price target for the stock from $183.00 to $120.00 in a research note on Wednesday, February 18th. Finally, JPMorgan Chase & Co. cut their price target on Icon from $175.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $153.00.

Icon Price Performance

Shares of NASDAQ ICLR opened at $136.07 on Friday. Icon has a 1-year low of $66.57 and a 1-year high of $211.00. The business has a 50-day moving average of $113.06 and a 200-day moving average of $141.46. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market capitalization of $10.99 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 3.57 and a beta of 1.23.

Icon (NASDAQ:ICLR) last issued its earnings results on Wednesday, June 3rd. The medical research company reported $2.52 earnings per share for the quarter, missing the consensus estimate of $3.13 by ($0.61). Icon had a return on equity of 10.58% and a net margin of 7.40%.The company had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the previous year, the company earned $3.43 EPS. Icon’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities analysts anticipate that Icon will post 11.53 EPS for the current fiscal year.

Institutional Trading of Icon

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in Icon by 26.6% during the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after buying an additional 975,268 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in Icon by 1.8% during the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after buying an additional 75,843 shares in the last quarter. Invesco Ltd. raised its stake in Icon by 9.6% during the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after buying an additional 329,266 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Icon by 10.3% during the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after purchasing an additional 310,236 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Icon by 8.7% during the 4th quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after purchasing an additional 239,808 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

More Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: BMO Capital Markets raised its target on Icon Plc to $160 from $130 and kept an outperform rating, suggesting meaningful upside potential. Benzinga
• Positive Sentiment: Barclays lifted its price target to $150 from $120, with an equal weight rating, signaling improved expectations for the stock. Tickerreport.com
• Positive Sentiment: Citigroup increased its target to $140 from $120, implying modest upside from current levels, though it kept a neutral stance. Tickerreport.com
• Neutral Sentiment: JPMorgan raised its target to $130 from $120 but kept a neutral rating, reflecting a more cautious view than some peers. Benzinga
• Neutral Sentiment: Icon reported fourth-quarter earnings that missed estimates, but revenue came in above expectations and the company highlighted strong bookings despite ongoing revenue challenges. Yahoo Finance
• Negative Sentiment: Icon disclosed a material weakness in internal controls, which raises concerns about financial reporting quality and potential regulatory risk. TipRanks
• Negative Sentiment: The company also cut FY 2026 EPS guidance to $10.00-$11.00, below Wall Street expectations, which likely pressured the stock after earnings. Financial News

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.